Citi has lowered its 2023 target for the Hang Seng Index to 29,600 points, with Tencent (00700.HK) and AIA (01299.HK) among its top picks for H shares.

Citi released a research report expressing cautious optimism about the outlook for China's stock market in the second half of 2026, favoring the technology and export sectors. The bank upgraded its investment rating for the insurance sector from "neutral" to "overweight." Citi expects insurance companies to benefit from higher investment returns from equities and inflows of bank deposits into insurance products. The bank set year-end 2026 target levels for the Hang Seng Index, CSI 300 Index, and MSCI China Index at 29,600 points (a 1.3% decrease from the previous target of 30,000 points), 5,600 points, and 92.0, respectively, while introducing a mid-2027 Hang Seng Index target of 30,500.

AASTOCKSMay 14 16:28

MSCI Global Small Cap Index May Adjustment: Meitu (01357) and 13 other stocks included, while Jianpu Technology (06166) and 20 others removed.

On May 13, MSCI (Ming Sheng Company), an international index compiler, announced the results of its quarterly index adjustment for May 2026. This adjustment will take effect after the market closes on May 29.

Zhitong FinanceMay 13 10:01

Citi: The fundamentals of China's healthcare industry continue to improve, with Wuxi Apptec (02359.HK), Wuxi Bio (02269.HK), and Ali Health (00241.HK) as top picks.

Citi issued a research report stating that the past fiscal year and first-quarter earnings season have confirmed a continued improvement in the fundamentals of China's healthcare industry, driven by innovative drugs and CDMOs (Contract Development and Manufacturing Organizations). The domestic medical technology, services, and pharmacy sectors have bottomed out. Innovation is yielding returns, with upfront payments and milestone payments from licensing deals boosting profitability. Sales of innovative drugs are accelerating, while order volumes for CXOs (Contract Research and Manufacturing Organizations) have reached new historical highs. Looking ahead, the bank anticipates a series of short-term catalysts, including data releases at ASCO 2026, sustained momentum in licensing deals, and the aftermath of pharmaceutical pricing reforms announced on April 14.

AASTOCKSMay 11 12:48

CR Healthcare (1515.HK): Marginal improvement in H2 2025 performance; transformation and innovation in 2026 to enhance growth resilience

The company achieved revenue of 9.176 billion yuan in 2025, representing a year-on-year decline of 6.9%, with a net profit attributable to shareholders of 496 million yuan, down 12.4% year-on-year. Excluding a one-time compensation payment of approximately 210 million yuan received under the Yanhua IOT agreement.

CSC Financial Co., Ltd.May 7 18:22

CR MEDICAL: ANNUAL REPORT 2025

HKEXApr 23 22:29 · Announcements

CICC has lowered its target price for China Resources Medical (01515.HK) to HKD 4.06, maintaining an 'Outperform' rating.

CICC issued a research report stating that China Resources Medical (01515.HK) is developing steadily, actively implementing measures to cut costs and improve efficiency while strengthening discipline. The firm maintained its net profit forecast for 2026 at RMB 499 million unchanged and introduced a new net profit forecast of RMB 510 million for 2027. Due to the decline in valuation of the H-share healthcare services sector, CICC reduced China Resources Medical's target price by 18.8% to HKD 4.06, maintaining its "Outperform" rating. (ca/u)~

AASTOCKSApr 9 10:12